Fig. 5: Oncogenic Kras Driven Lung Adenocarcinoma is Accelerated in Tumors Lacking iASPP.
From: Regulation of immunological tolerance by the p53-inhibitor iASPP
A Schematic of initiation of lung adenocarcinoma in iASPPfl/fl (i, n = 2), KrasLSL−G12D/+ (K, n = 3), or KrasLSL−G12D/+;iASPPfl/fl (Ki, n = 3) mice with intranasal inhalation of adenoviral Cre (Ad-Cre). Lungs and mediastinal lymph node (mLN) were collected 15 weeks post-infection (pi). B Proportion of lung tumors classified by histological grade. P value computed by Exact Contingency test. C HE stains of lung lobes 15 weeks after tumor initiation. Scale, 5 mm (top) and 250 μm (bottom). D Quantification of tumor burden of lung tumors in (C). Tumor burden was calculated as total tumor area divided by total area of each lung lobe. E HE stains of lung lobes 15 weeks after tumor initiation. Arrows indicate tertiary lymphoid structures (TLS). Scale, 250 μm. F Quantification of numbers of tertiary lymphoid structures (TLS) present per tumor from mice 15 weeks after tumor initiation.
